Pierluigi Scalia, born in Caltanissetta, is a physician-scientist and an Italian-American social entrepreneur (class 1968). He graduated in Medicine and Surgery at the University of Catania, than he continued his career in the United States that granted him the the citizenship based upon scientific merits and the Italian title of doctor of endocrine-molecular sciences. Two decades of experience in basic and applied research in the academic and private sector backed by international scientific publications and patented cancer biomarker research. He is the author of several peer-reviewed scientific articles in oncology and owner of patented research on a tumorigenic mechanism of proliferation and blood vessel formation shared by solid tumors. His expertise includes the identification of cancer biomarkers, the validation of molecular and genomic tests, the management of complex multidisciplinary projects, professional and academic training, patenting, biotech start-up and consultancies on international projects in health and oncology (such as the “Tumaini” project in Tanzania in 2013). Pierluigi is also a US certified technologist in Molecular Biology and Molecular Pathology and co-founder and scientific director of two biotech start-up companies (in California and Delaware). He was professor at various American Colleges and professor in Genetics at the Department of Biology & Chemistry of Azusa University in Los Angeles. Currently he is an adjunct associate professor at the Sbarro Institute for Cancer Research and Molecular Medicine at Temple University in Philadelphia. Among his professional objectives is the establishment of an International research Center in support of personalized oncology in Sicily. This project was conveyed in a non-profit organization formed in 2014 in Caltanissetta, Italy (The “Istituto Somatogene per la Oncologia Personalizzata e la Ricerca OncoGenomica, ISOPROG)”. ISOPROG has received important affiliations and the availability an internationally renown hosting site for the development of the proposed research center, namely the buildings of the AVERNA company (now owned by Campari s.p.a.).
Founder & Scientific Director
Updated on 2016-06-15T17:34:14+02:00, by .